Another robot deal for J&J shows up lack of Verb results
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Healx lands $56m to power artificial intelligence-led drug discovery
Healx's "hypothesis-free" approach proves a big draw to investors despite the early-stage nature of the group's projects.
Venture cash gets even more concentrated
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
A new reality for Immunocore
A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.
With new unicorn status, CMR Surgical sets profitability target
CMR Surgical’s private round is the largest ever venture deal for a European medtech. And the point is to get to profitability, not flotation.
Private European companies enjoy their own treasure bath
The biotech financing scene in Europe continues to be dwarfed by the US, but on some measures the region is on an even footing.
Venture investing dips again for biopharma
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
Medtech VC and the billion-dollar era
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
MD Start bucks the trend for later-stage medtech investing
Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.
